Peginterferon Alfa-2a Injection Shortage
Last Updated: May 2, 2025
Status: Current
Products Affected - Description
-
- Pegasys subcutaneous solution for injection, Summit SD, 180 mcg/0.5 mL, 0.5 mL prefilled syringe, 4 syringes in a monthly convenience pack, NDC 82154-0451-04
- Pegasys subcutaneous solution for injection, Summit SD, 180 mcg/mL, 1 mL single dose vial, NDC 82154-0449-01
Reason for the Shortage
-
- Summit SD is the distributor of Pegasys in the US. Pharma& manufactures Pegasys and is working to expand bio-manufacturing capabilities at the manufacturing plant.
Available Products
-
- There is insufficient supply for usual ordering
Estimated Resupply Dates
-
- Summit SD has Pegasys 180 mcg/mL 1 mL vials and 180 mcg/0.5 mL prefilled syringes on allocation. The company expects supply to become more limited through 4th quarter 2025. The company estimates additional product will be available in the first half of 2026.
Alternative Agents & Management
-
- Ropeginterferon alfa-2b-njft (Besremi) is a preferred alternative in patients with both low-risk (symptomatic) and high-risk polycythemia vera (PV) in the NCCN Clinical Practice Guidelines in Oncology. This information can be found at https://www.besremihcp.com/.
Updated
Updated May 2, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 10, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.